Brief: Gensight Biologics End-September Cash And Cash Equivalents Up At 18.1 Million Euros

Gensight Biologics SA

15/10/2020 06:49

Oct 15 (Reuters) - Gensight Biologics SA  SIGHT.PA :
    * CASH AND CASH EQUIVALENTS TOTALED EUR 18.1 MILLION AS OF
SEPTEMBER 30, 2020, VERSUS EUR 16.8 MILLION AS OF JUNE 30, 2020
    * WE CONTINUE TO PREPARE FOR FILING OF BIOLOGICS LICENSE
APPLICATION WITH U.S. FOOD AND DRUG ADMINISTRATION DURING SECOND
HALF OF 2021 - CEO
    * TEMPORARY AUTHORIZATION FOR USE (ATU) OF LUMEVOQ: PATIENTS
HAVE
BEEN SCHEDULED FOR TREATMENT IN OCTOBER
    * WE HAVE BEEN ABLE TO SECURE SIGNIFICANT FINANCING THIS
YEAR TO
FUND THE LAST MILE OF LUMEVOQ WITH MINIMAL DILUTION TO
SHAREHOLDERS TO AT LEAST MID- 2021 - CFO
    * LUMEVOQ: INJECTIONS PRICED AT €700,000 PER PATIENT,
EXPECTED TO
GENERATE REVENUES PRIOR TO REGULATORY APPROVAL AND REIMBURSEMENT
IN FRANCE

Source text for Eikon:  ID:nBw3YVvBHa 
Further company coverage:  SIGHT.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))